ReviewFrontiers in neuroscience2022
Psychedelic Cognition-The Unreached Frontier of Psychedelic Science.
Review in Frontiers in neuroscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 4 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- Effects of LSD, DMT and psilocybin on cognitive and psychological functions: A systematic review of the literature.Journal of psychopharmacology (Oxford, England) · 2026Pooled it
- Augmentation Therapy With Serotonin 5-HTNeuropsychopharmacology reports · 2025Pooled it
- Acute effects of psilocybin on attention and executive functioning in healthy volunteers: a systematic review and multilevel meta-analysis.Psychopharmacology · 2025Pooled it
- Cognitive functioning associated with acute and subacute effects of classic psychedelics and MDMA - a systematic review and meta-analysis.Scientific reports · 2024Pooled it
- Greater subjective effects of a low dose of LSD in participants with depressed mood.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Trial
- Predictors of the Effectiveness of Psychedelics in Treating Depression-A Scoping Review.International journal of molecular sciences · 2026Article
- Cognitive control as a transdiagnostic mechanism of action in psychedelic effects.Cognitive, affective & behavioral neuroscience · 2026Review
- Phenomenology of Psychedelic Experiences and Psychedelic-Associated Distressing Effects: Quantifying Subjective Experiences.Current topics in behavioral neurosciences · 2026Review
- IndolethylamineACS chemical neuroscience · 2025Article
- Acute effects of psilocybin on the dynamics of gaze fixations during visual aesthetic perception.Scientific reports · 2025Article
- Psilocybin-induced modulation of visual salience processing.Neuroscience of consciousness · 2025Article
- Neuropsychological profiles of patients suffering from hallucinogen persisting perception disorder (HPPD): A comparative analysis with psychedelic-using and non-using controls.Scientific reports · 2024Article
- Divergent Effects of Ketamine and the Serotoninergic Psychedelic 2,5-Dimethoxy-4-Iodoamphetamine on Hippocampal Plasticity and Metaplasticity.Psychedelic medicine (New Rochelle, N.Y.) · 2024Article
- Psilocybin's effects on cognition and creativity: A scoping review.Journal of psychopharmacology (Oxford, England) · 2023Article
- An encounter with the self: A thematic and content analysis of the DMT experience from a naturalistic field study.Frontiers in psychology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psychedelic compounds hold the promise of changing the face of neuroscience and psychiatry as we know it. There have been numerous proposals to use them to treat a range of neuropsychiatric conditions such as depression, anxiety, addiction and PTSD; and trials to date have delivered positive results in favor of the novel therapeutics. Further to the medical use, the wider healthy population is gaining interest in these compounds. We see a surge in personal use of psychedelic drugs for reasons not limited to spiritual enhancement, improved productivity, aiding the management of non-pathological anxiety and depression, and recreational interests. Notably, microdosing-the practice of taking subacute doses of psychedelic compounds-is on the rise. Our knowledge about the effects of psychedelic compounds, however, especially in naturalistic settings, is still fairly limited. In particular, one of the largest gaps concerns the acute effects on cognition caused by psychedelics. Studies carried out to date are riddled with limitations such as having disparate paradigms, small sample sizes, and insufficient breadth of testing on both unhealthy
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.